Israel HealthCare Ventures

Venture Capital Active Tel Aviv-Yafo, Israel Est. 2000
Last updated 2026-06-18
Portfolio
10
in our dataset
Rounds participated
15
Rounds led
2
Rounds' value
$131.5M
total disclosed, rounds participated
Stages
C Round, F Round, A Round, B Round, Seed, G Round, D Round, E Round

About

Israel HealthCare Ventures (IHCV) is an Israeli life sciences venture fund. To date, IHCV I and IHCV II have cumulatively invested approximately $135 million in 27 companies. IHCVs portfolio includes companies in medical fields including cardiology, orthopedics, oncology, general surgery, gastroenterology, esthetics, central nervous system, and others. It covers therapeutic and diagnostic technologies as well as rehabilitation, drug delivery, and consumer healthcare. About 75% of the funds portfolio consists of medical device companies, with the rest in pharmaceuticals and biotechnology. IHCV is a venture fund that operates much like a long-term investment company. It pursues a hands-on, personal, and informal approach, providing portfolio companies with professional advice, ongoing management support, and an extensive network of contacts throughout the global medical and financial arenas. The fund is not limited by preset policies that define the stage, discipline, or size of investment.

Portfolio · 10

Investment activity

3 portfolio exits on record.

Portfolio by sector

Health Tech & Life Sciences8
Aerospace, Defense & HLS1
Retail Platforms1

Q&A

What is Israel HealthCare Ventures' primary investment focus?
Israel HealthCare Ventures is an Israeli life sciences venture fund, with approximately 75% of its portfolio in medical device companies and the remainder in pharmaceuticals and biotechnology.
How many companies has Israel HealthCare Ventures invested in through its first two funds?
Through IHCV I and IHCV II, Israel HealthCare Ventures has cumulatively invested approximately $135 million in 27 companies.
Can you name a notable exit for Israel HealthCare Ventures?
In October 2018, Israel HealthCare Ventures saw an exit with Gamida Cell, which went public on NASDAQ with a valuation of $210 million.
What is Israel HealthCare Ventures' approach to investments?
Israel HealthCare Ventures operates like a long-term investment company, adopting a hands-on approach by providing professional advice, ongoing management support, and an extensive network to its portfolio companies.
What types of medical fields does Israel HealthCare Ventures' portfolio cover?
Israel HealthCare Ventures' portfolio includes companies in cardiology, orthopedics, oncology, general surgery, gastroenterology, esthetics, and central nervous system, among others.
Who is a key member of the Israel HealthCare Ventures team?
Hadar Ron is a Co-founder & Managing Partner at Israel HealthCare Ventures.
What was a significant acquisition exit for Israel HealthCare Ventures?
In December 2009, Israel HealthCare Ventures had an exit when Optonol was acquired by Alcon for $150 million.
What is one of Israel HealthCare Ventures' portfolio companies in the medical aesthetic device sector?
Candela, a company focused on medical aesthetic devices, is one of Israel HealthCare Ventures' portfolio companies.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)